Abstract: An advanced map DB 43 stored on a server device 4 includes pulse type information that is configuration information for detecting a landmark using a LIDAR 2. By sending request information D1 including own vehicle position information, the vehicle mounted device 1 receives response information D2 including pulse type information corresponding to a landmark around the own vehicle position and controls the LIDAR 2 on the basis of the received pulse type information.

Abstract: A stable and high-purity protected pseudouridine in crystal form is provided represented by the following structural formula: wherein M represents a trityl group or a derivative thereof, which is a useful material for producing an RNA oligomer or a similar substance. A method for producing the crystalline protected pseudouridine is also provided, which method includes crystallizing a protected pseudouridine from a solution containing the protected pseudouridine, by use of an ester solvent and/or an alcoholic solvent. The method, which does not need a silica gel column treatment, can be performed in a simple manner, does not impose a load on the environment, and realizes low-cost production of a target crystalline protected pseudouridine.

Abstract: A stable and high-purity protected pseudouridine in crystal form is provided represented by the following structural formula: wherein M represents a trityl group or a derivative thereof, which is a useful material for producing an RNA oligomer or a similar substance. A method for producing the crystalline protected pseudouridine is also provided, which method includes crystallizing a protected pseudouridine from a solution containing the protected pseudouridine, by use of an ester solvent and/or an alcoholic solvent. The method, which does not need a silica gel column treatment, can be performed in a simple manner, does not impose a load on the environment, and realizes low-cost production of a target crystalline protected pseudouridine.

Abstract: The invention provides 4′-C-ethynyl purine nucleosides represented by formula [I]: wherein B represents a base selected from the group consisting of purine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.

Abstract: The present invention relates to 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosines having excellent antitumor activity, represented by formula [I]: ##STR1## wherein R represents a hydrogen atom or a phosphoric acid residue, and to a process for the production and use thereof.